Subscribe

Thank you for your interest in a GaBI Journal subscription.

GaBI Journal is an international journal publishing independent, high quality, authoritative and peer reviewed scientific articles concerning any aspect of the research into and development of cost-effective medicines, irrespective of their source. It includes expert analysis, review articles, briefings and updates on all aspects of comparative bioavailability, bioequivalence studies (traditional and biopharmaceutical), drug safety and risk management, drug production, analytical manufacturing methodology, drug/formulation development, biopharmaceutical and generics regulatory issues, healthcare policies and medicines policies, health economics, patient information, drug stereoisomerism including chirality, etc.  Each issue publishes papers which are of direct relevance to healthcare professionals and practitioners and that meet the highest scientific standards.

We continuously strive to provide you with the most up-to-date information on research into and development of the science of generics and biosimilar medicines relevant to your profession.

To help us further develop GaBI, we would be grateful if you could recommend your colleagues and users at your institution or associates in your professional network to subscribe to GaBI Journal.

GaBI Journal is committed to its subscribers via sharing of professional and peer reviewed information supporting the development of cost-effective treatments.

Sign-up here to receive an email alert on the content of forthcoming issues.

GaBI’s mission – Building trust in cost-effective treatments.  Support GaBI.

Click here to subscribe or submit your subscription via the online Subscription Form below.

Subscription Form


















All fields are required

GaBI Journal is distributed free to selected healthcare professionals in clinical practice (physicians and pharmacists) and healthcare policies, pharmaceutical experts and scientists worldwide. Subscription is available to individuals, institutions, universities, hospitals, corporations and students.

Subscription rates cover four (4) issues of GaBI Journal per year. Single print copy = € 99.

SUBSCRIPTION RATES 2017
Category Europe Non-Europe
Individual* € 588 € 654
Hospital/University € 1,078 € 1,144
Corporate** € 2,613 € 2,701
Student* € 490 € 556

Subscription starts automatically with the next available issue after receipt of payment.
*Individuals, students and organisations in the EU without a VAT number are subject to 21% VAT Belgian Government tax. The 21% VAT is not applicable to organisations outside of the EU.
**Corporate subscriptions receive five (5) copies of the journal.

We accept American Express, MasterCard and Visa. Please indicate the cardholder’s name, card number, expiry date and CVC code. Credit card orders will be charged in Euros. Payment via PayPal is also acceptable.

Back issues, PDF licences and reprints are available for purchase. Contact us for more details.

GaBI Journal – print ISSN: 2033-6403; online ISSN: 2033-6772

Bulk subscriptions

Contact us for all requests from industry, agencies, and companies regarding bulk subscriptions.

Change of address notice

Both subscriber’s old and new addresses should be sent to us via email at least six weeks in advance.

Claims

When claims for undelivered or damaged issues are made within four months of publication of the issue, a complimentary replacement issue will be provided.

Source URL: http://gabi-journal.net/gabi-journal/how-to/subscribe


One Response to Subscribe

  1. Pingback: Guest Blog: GaBI – Building trust in cost-effective treatments - Total Biopharma : Total Biopharma


Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048